Skip to main content
. 2021 Apr 21;88(3):291–316. doi: 10.1177/00243639211005121

Table 22.

Estimated Economic Impact of Combined Oral Contraceptives (COCs) due to Decreased Prevalence of Uterine Cancer.

Women ≥18 in 2010 census Ever use of COCs Prevalence
119,292,801 94,599,191 0.006655
Estimated women on the pill at risk 629,558
Adjusted estimate 828,366 0.76 (0.73–0.78) Relative risk
Decrease in cases −198,808
Annual cost per patient with uterine cancer US$3,160.35
Estimated total costs −US$628,302,197